Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Fate Therapeutics Inc(FATE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FATE
10/02/2026: FATE (1-star) is currently NOT-A-BUY. Pass it for now.
Fate Therapeutics is a clinical-stage biotechnology company that leverages induced pluripotent stem cell (iPSC) technology to develop off-the-shelf immunotherapies for cancer and autoimmune diseases. Its main strength lies in its proprietary platform, which aims to standardize cell therapy production and address the challenges of current patient-specific treatments. The primary investment story rests on the potential for its clinical pipeline to achieve regulatory success and disrupt the cell therapy market. However, the company faces significant risks related to its lack of commercial revenue, high cash burn, and the inherent challenges of clinical-stage biotechnology. It is best suited for growth-oriented, risk-tolerant investors who are focused on the long-term potential of cell-based medicines.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential through innovative technology, but this is tempered by clinical-stage risk. |
| Momentum investor | Mixed fit | Momentum is highly dependent on positive clinical trial readouts or strategic partnership announcements. |
| Value investor | Weak fit | The company lacks earnings and historical cash flow, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Fate does not pay a dividend and reinvests all capital into research. |
| Low-risk investor | Weak fit | The high volatility and clinical risk profile are generally unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Stock prices are sensitive to clinical data updates and sector sentiment. |
| Valuation risk | High | Without commercial revenue, valuation is highly speculative. |
| Competition risk (Biotech/Cell therapy) | Medium / high | Large incumbents possess significant resources to outpace or challenge new technologies. |
| Business quality | Medium | The company holds strong intellectual property but faces execution risk in proving product efficacy. |
| Dividend income | Low / none | The company does not generate the profits required for dividend distributions. |
| Execution risk | High | Success depends on complex manufacturing and positive human clinical trial outcomes. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -56.21% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 275.59M USD | Price to earnings Ratio - | 1Y Target Price 5.74 |
Price to earnings Ratio - | 1Y Target Price 5.74 | ||
Volume (30-day avg) 1.4M shares | Beta 2.55 | 52 Weeks Range 0.95 - 3.23 | Updated Date 10/01/2026 |
52 Weeks Range 0.95 - 3.23 | Updated Date 10/01/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.02 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Revenue recognized from strategic partnerships and technology licensing agreements. | The company earns money primarily through research collaborations rather than product sales. |
| Geography | Primary operations are based in the United States, with global reach through research and clinical partners. | The company's primary market and development hub is the US biotech sector. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 213.67M | Price to Sales(TTM) 42.46 |
Enterprise Value 213.67M | Price to Sales(TTM) 42.46 | ||
Enterprise Value to Revenue 32.92 | Enterprise Value to EBITDA -2.59 | Shares Outstanding 119.82M | Shares Floating 105.22M |
Shares Outstanding 119.82M | Shares Floating 105.22M | ||
Percent Insiders 1.06 | Percent Institutions 69.05 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Fate Therapeutics Inc
Exchange NASDAQ | Headquarters San Diego, CA, United States | ||
IPO Launch date 2013-10-01 | President, CEO & Director Dr. Bahram Valamehr M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 161 | Website https://www.fatetherapeutics.com |
Full time employees 161 | Website https://www.fatetherapeutics.com | ||
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.